A prospective evaluation of pulmonary, cardiac, and hepatic function (fn) in ‘tAnGo’: A randomized phase III trial of gemcitabine (G) in paclitaxel (T)-containing, epirubicin/cyclophosphamide ...
Conclusion: AT significantly improves TTP and ORR compared with AC in patients with MBC, but there is no difference in OS. AT represents a valid option for the treatment of MBC. From the University of ...
San Antonio, TX – December 5, 2003 – A Docetaxel (Taxotere®)-based regimen reduced the relative risk of death in women with early stage breast cancer by 30 percent and lowered the relative risk of the ...
Dr. Lisa Carey answers the question: 'Drugs, Schedules For Chemo Treatments?' — -- Question: What kinds of drugs, timetables and possible side effects can be expected with the following commonly ...
The use of high-dose therapy (HDT) with bone marrow and/or peripheral blood progenitor cell (PBPC) transplantation for the treatment of metastatic breast cancer (MBC ...
One method for increasing dose intensity in high risk patients in order to achieve the most benefit of maximum dose intensity is reducing the conventional drug dose intervals dose-dense regimen.
Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk ...
Pictured below is a woman with microscopic polyangiitis treated with intravenous cyclophosphamide and high doses cytoxan price in india corticosteroids. After several cyclophosphamide treatments. When ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback